An observational post‐authorization safety study (PASS) of naloxegol drug utilization in four European countries

• Published in: Pharmacoepidemiology and drug safety 2024-01, Vol.33 (1), p.e5710-n/a
• Main Authors: Kvarstein, Gunnvald, Kindlundh‐Högberg, Anna MS, Ould Setti, Mounir, Namane, Rafik, Muzwidzwa, Ruvimbo, Richter, Hartmut, Hakkarainen, Katja M.
• Format: Article
• Language: English
• Subjects: Aged; Analgesics, Opioid - adverse effects; Cohort Studies; Comorbidity; Constipation; Constipation - chemically induced; Constipation - drug therapy; Constipation - epidemiology; discontinuation; drug utilization; Female; Humans; laxative; Laxatives; Laxatives - adverse effects; Male; Middle Aged; Morphinans - adverse effects; Moventig; Naloxegol; Narcotics; Opioids; opioid‐induced constipation; PAMORA; Patients; Polyethylene Glycols - adverse effects
• ISSN: 1053-8569; 1099-1557; 1099-1557
• DOI: 10.1002/pds.5710

Purpose Naloxegol has been shown to be an efficient alternative to treat opioid‐induced constipation (OIC). This study aimed at describing the characteristics of naloxegol users and assessing patterns of naloxegol use and associated factors. Methods This drug utilization cohort study used observational registry data on patients newly prescribed naloxegol in four European countries. Patient characteristics and patterns of naloxegol use and associated factors were described. Results A total of 17 254 naloxegol users were identified across the countries. Their median age was 56–71 years, and each country had a majority of women (ranging 57.5%–62.9%). Multiple comorbidities, including cancer, were common. Natural opium alkaloids and osmotically acting laxatives (excluding saline) were the most frequently used opioids and laxatives. Overall prior use of opioids ranged from 91.9% to 99.6% and overall prior use of laxatives ranged from 69.9% to 92.4%. Up to 77.7% had prior use of medications with interaction potential, and up to 44.5% used them concurrently with naloxegol. Naloxegol was discontinued by 55.1%–90.9% of users, typically during the first 30 days. Approximately 10%–30% switched to or augmented the treatment with another constipation medication or restarted naloxegol after discontinuation. Augmentation with another constipation medication was relatively common, suggesting that naloxegol was used for multifactorial constipation. Conclusion The present study reflects real‐world clinical use of naloxegol, including in vulnerable patient groups. Some naloxegol users lacked laxative or regular opioid use within six months before index date or used naloxegol concomitantly with medications presenting an interaction potential.